@article{C-MOREPHOSP-COVID:2023:10.1016/S2213-2600(23)00262-X,
author = {C-MOREPHOSP-COVID, Collaborative Group},
doi = {10.1016/S2213-2600(23)00262-X},
journal = {The Lancet Respiratory Medicine},
pages = {1003--1019},
title = {Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study},
url = {http://dx.doi.org/10.1016/S2213-2600(23)00262-X},
volume = {11},
year = {2023}
}

Download

TY  - JOUR
AB  - INTRODUCTION: The multiorgan impact of moderate to severe coronavirus infections in the post-acute phase is still poorly understood. We aimed to evaluate the excess burden of multiorgan abnormalities after hospitalisation with COVID-19, evaluate their determinants, and explore associations with patient-related outcome measures. METHODS: In a prospective, UK-wide, multicentre MRI follow-up study (C-MORE), adults (aged ≥18 years) discharged from hospital following COVID-19 who were included in Tier 2 of the Post-hospitalisation COVID-19 study (PHOSP-COVID) and contemporary controls with no evidence of previous COVID-19 (SARS-CoV-2 nucleocapsid antibody negative) underwent multiorgan MRI (lungs, heart, brain, liver, and kidneys) with quantitative and qualitative assessment of images and clinical adjudication when relevant. Individuals with end-stage renal failure or contraindications to MRI were excluded. Participants also underwent detailed recording of symptoms, and physiological and biochemical tests. The primary outcome was the excess burden of multiorgan abnormalities (two or more organs) relative to controls, with further adjustments for potential confounders. The C-MORE study is ongoing and is registered with ClinicalTrials.gov, NCT04510025. FINDINGS: Of 2710 participants in Tier 2 of PHOSP-COVID, 531 were recruited across 13 UK-wide C-MORE sites. After exclusions, 259 C-MORE patients (mean age 57 years [SD 12]; 158 [61%] male and 101 [39%] female) who were discharged from hospital with PCR-confirmed or clinically diagnosed COVID-19 between March 1, 2020, and Nov 1, 2021, and 52 non-COVID-19 controls from the community (mean age 49 years [SD 14]; 30 [58%] male and 22 [42%] female) were included in the analysis. Patients were assessed at a median of 5·0 months (IQR 4·2-6·3) after hospital discharge. Compared with non-COVID-19 controls, patients were older, living with more obesity, and had more comorbidities. Multiorgan abnormalities on MR
AU  - C-MOREPHOSP-COVID,Collaborative Group
DO  - 10.1016/S2213-2600(23)00262-X
EP  - 1019
PY  - 2023///
SN  - 2213-2600
SP  - 1003
TI  - Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study
T2  - The Lancet Respiratory Medicine
UR  - http://dx.doi.org/10.1016/S2213-2600(23)00262-X
UR  - https://www.ncbi.nlm.nih.gov/pubmed/37748493
UR  - https://www.sciencedirect.com/science/article/pii/S221326002300262X
UR  - http://hdl.handle.net/10044/1/107531
VL  - 11
ER  - 

Download